Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
POFUT1
REST API REST API
Homo sapiens
POFUT1 is differentially expressed in 157 experiments: 73 organism parts: bone marrow, skin, ... (71 more);, 142 disease states: normal, lung adenocarcinoma, ... (140 more);, 29 cell types 94 cell lines 51 compound treatments and 54 other conditions.
Synonyms O-Fuc-T, O-FUT, KIAA0180, FUT12
Orthologs Pofut1 (Rattus norvegicus)   ENSCING00000004769 (Ciona intestinalis)   pofut1 (Danio rerio)   Q8AWB4_CHICK (Gallus gallus)   Q7YRE6_BOVIN (Bos taurus)   Pofut1 (Mus musculus)   O-fut1 (Drosophila melanogaster)   pofut1 (Xenopus tropicalis)   Q00P48_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, embryo development, endoplasmic reticulum, regulation of transcription, DNA-dependent, membrane, O-glycan processing, fucose metabolic process, somitogenesis, fucosyltransferase activity, transferase activity, transferring glycosyl groups, heart development, peptide-O-fucosyltransferase activity, carbohydrate metabolic process, nervous system development, Notch signaling pathway, protein O-linked glycosylation
UniProt Accession Q9H488, B4DUV4
InterPro Term GDP-fucose protein O-fucosyltransferase
Search EB-eye ENSG00000101346
Show more properties
Experimental Factors
organism part

studied in E-GEOD-15765, E-AFMX-5, E-MEXP-433, E-GEOD-1563, E-TABM-145, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-19397, E-GEOD-18005, E-GEOD-2450, ... (25 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-995, E-MTAB-37, E-GEOD-24147
T47D
3
E-MEXP-440, E-GEOD-3529, E-MTAB-62
Caco-2
2
E-MTAB-62, E-GEOD-1474
CCRFCEM
2
1
E-GEOD-24147
293t-tva
1
1
E-MTAB-62
GM12892
1
E-GEOD-19466
88 more value(s).


cell type

studied in E-GEOD-10797, E-AFMX-5, E-GEOD-21668, E-GEOD-3920, E-GEOD-1460, ... (23 experiments)

Factor Value U/D Experiments
CD34+
2
2
E-TABM-145, E-AFMX-5
CD14+ monocyte
3
2
E-TABM-145, E-AFMX-5
stromal cell
2
E-GEOD-1460, E-GEOD-10797
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
mesenchymal stem cell
1
E-GEOD-9894
cardiac myocyte
1
E-MTAB-25
23 more value(s).


disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-13355, E-MEXP-66, E-MTAB-62, ... (30 experiments)

Factor Value U/D Experiments
glioblastoma
2
E-GEOD-4290, E-GEOD-4412
acute lymphoblastic leukemia
2
E-GEOD-5824, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
melanoma
2
E-MTAB-62, E-GEOD-7307
hepatocellular adenoma
1
E-MTAB-62
monoclonal gammopathy of unknown significance
1
E-MTAB-62
136 more value(s).


Compound treatment

studied in E-MEXP-1269, E-MEXP-2590, E-MTAB-798, E-GEOD-412, E-MEXP-2645, ... (11 experiments)

Factor Value U/D Experiments
tetradecylthioacetic acid 75 micromolar
1
E-MEXP-2590
tolbutamide 400 micromolar
1
E-MTAB-798
meloxicam 50 micromolar
1
E-MTAB-798
control
1
E-GEOD-995
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
45 more value(s).


RNAi

studied in E-MEXP-101, E-GEOD-3697

Factor Value U/D Experiments
Luc siRNA
1
E-GEOD-3697
SIM2s
1
1
E-MEXP-101
HSF1 siRNA #1
1
E-GEOD-3697
control
4
1
E-MEXP-101


alive at endpoint
studied in E-GEOD-4922

biosource provider
studied in E-GEOD-19466, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cancer site
studied in E-GEOD-4271

cellular component
studied in E-GEOD-1400

chromosomal aberration
studied in E-TABM-125

clinical history
studied in E-GEOD-19743, E-TABM-125, E-MTAB-691, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-2034, ... (7 experiments)

clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

developmental stage
studied in E-GEOD-19743, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

disease staging
studied in E-GEOD-89, E-GEOD-21138

environmental stress
studied in E-GEOD-1643, E-GEOD-3720

estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922

genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-361

genotype
studied in E-GEOD-3494, E-MEXP-421, E-GEOD-9761, E-GEOD-18005, E-GEOD-8141 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

growth condition
studied in E-TABM-263, E-GEOD-15543, E-GEOD-19864

histology
studied in E-TABM-276

individual
studied in E-MTAB-197, E-GEOD-1432, E-GEOD-6919, E-GEOD-16363, E-GEOD-21610, ... (18 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254

irradiate
studied in E-GEOD-2742

library source
studied in E-GEOD-19323

lymph node status
studied in E-GEOD-6532

material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

metastasis
studied in E-GEOD-18105

molecular subtype
studied in E-GEOD-21653

organism
studied in E-GEOD-1801

organism status
studied in E-GEOD-19188

performer
studied in E-LGCL-5

phenotype
studied in E-GEOD-1309, E-GEOD-1460, E-GEOD-5824

population
studied in E-GEOD-4922, E-GEOD-4342

progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

progression free survival of days
studied in E-GEOD-5851

protocol type
studied in E-GEOD-3254, E-GEOD-19249, E-GEOD-19246

pt
studied in E-GEOD-21653

sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

sampling time point
studied in E-GEOD-19743, E-MTAB-798, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

stimulus
studied in E-GEOD-20114

subtype
studied in E-GEOD-24283

survival time
studied in E-GEOD-19188

test result
studied in E-TABM-276

treatment
studied in E-GEOD-16837, E-GEOD-34635, E-GEOD-19246

tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 1.418 secs.
 
Gene Expression Atlas 2.0.13- 4/23/12 11:55:46 AM